adalimumab Archives | Page 26 of 49

Health Canada issues NOC for Idacio®

by Bioblast Editor | Oct 30, 2020 | Biosimilars updates

Fresenius Kabi receives a Notice of Compliance relating to its biosimilar adalimumab (50mg/mL), Idacio®.

Two amicus briefs filed in support of Humira® antitrust legislation

by Bioblast Editor | Oct 12, 2020 | Biosimilars updates

Two amicus briefs were filed in the 7th Circuit Court of Appeals in support of the plaintiffs in the Humira® (adalimumab) antitrust legislation UFCW Local 1500 Welfare Fund v AbbVie, Inc. The US Public Interest Research Group jointly filed its brief with Consumer...

Oxford commences Ph II AmAb trials in COVID-19 patients

by Bioblast Editor | Sep 30, 2020 | Biosimilars updates

The University of Oxford announces it has commenced Ph II trials of adalimumab as a treatment for patients with COVID-19. The trial will enrol up to 750 patients from community care settings throughout the UK and is funded by the COVID-19 Therapeutics Accelerator, an...

China’s NMPA approves Sulinno®

by Bioblast Editor | Sep 3, 2020 | Biosimilars updates

Innovent Biologics announces China’s NMPA has approved Sulinno® for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis.

Cadila launches Cadalimab® in India

by Bioblast Editor | Aug 28, 2020 | Biosimilars updates

Cadila Pharmaceuticals launches Cadalimab® (biosimilar adalimumab) in India. Cadalimab® is available in 40mg/0.8mL injection and is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. This is...